NCT02724423View on ClinicalTrials.gov

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 10, 2019

Study Completion Date

September 10, 2019

Conditions
Acute Repetitive Seizures
Interventions
DRUG

NRL-1

Trial Locations (4)

19107

Thomas Jefferson University, Philadelphia

22903

University of Virginia, Charlottesville

38103

Le Bonheur Children's Hospita, Memphis

63110

Washington University School of Medicine, St Louis

Sponsors

Lead Sponsor

Neurelis, Inc.
All Listed Sponsors
lead

Neurelis, Inc.

INDUSTRY

NCT02724423 - Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects | Biotech Hunter | Biotech Hunter